Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Results Earnings Call for the Audited Financial Results for quarter and year ended march 31, 2026 is enclosed herewith along with dial in details and link for joining the call. Kindly ....
Regulatory Filings Classification · 25% confidence The document is a formal notice to stock exchanges under SEBI LODR Regulation 30 announcing the scheduling of an earnings call to discuss financial results. It does not contain any financial data, earnings highlights, or actual presentation slides, nor is it the transcript of the call. It is a regulatory announcement/disclosure rather than an earnings release or report itself. Therefore it falls under general regulatory filings (RNS).
2026-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is an official notice under SEBI LODR Reg.30 informing stock exchanges and investors of an upcoming earnings conference call to discuss the audited financial results for the quarter and year ended March 31, 2026. It does not contain actual financial results (so it’s not an Earnings Release), nor is it a transcript or the financial report itself. It is a regulatory announcement of an event, so it falls under the general Regulatory Filings category (RNS).
2026-05-23 English
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve In terms of Regulation ....
Regulatory Filings Classification · 75% confidence The document is an official notice to stock exchanges under SEBI Listing Obligations notifying the date and agenda of an upcoming Board of Directors meeting. It does not contain financial results or actual report data, nor does it announce changes in board or management or dividend details. This is a routine compliance filing under listing regulations rather than a financial report or change notice. It thus falls into the general regulatory announcements category.
2026-05-20 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding an update on an inspection by the US FDA at the company's manufacturing facility. It mentions the issuance of a Form 483 with one minor observation and the subsequent Establishment Inspection Report indicating successful completion. The letter references compliance with SEBI (LODR) Regulations, 2015, specifically Regulation 30, which pertains to continuous disclosures of material events. The document is short (2196 characters) and serves as an announcement of an event rather than a detailed report or financial statement. It does not contain financial data, audit results, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2026-04-22 English
Shareholders meeting
Regulatory Filings
2026-04-11 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended March 31, 2026. It is issued by the Registrar and Share Transfer Agent and addressed to stock exchanges. The content is a compliance certificate rather than a financial report or announcement of financial results. The document length is 3554 characters, which is relatively short and primarily contains a certification letter. According to the Certification Rule, such officer certifications or compliance confirmations should be classified as Regulatory Filings (RNS).
2026-04-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.